Health status and quality of life in patients with psoriasis: An Iranian cross-sectional survey

Mahshid Moradi, Fanni Rencz, Valentin Brodszky, Ahmad Moradi, Orsolya Balogh, L. Gulácsi

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Background: Psoriasis has a significant negative impact on patients’ health-related quality of life (HRQOL). This study aims to evaluate HRQOL of adult patients with psoriasis in Iran, and explore the relationship between general and disease-specific outcome measures in psoriasis. Methods: Between May and August 2013, a cross-sectional questionnaire survey of consecutive outpatients was conducted at a single clinic in Shiraz, Iran. HRQOL was assessed by the general measure EuroQol 5 dimensions (EQ-5D), visual analogue scale (EQ VAS), and the disease-specific Dermatology Life Quality Index (DLQI). Disease severity was measured by the Psoriasis Area and Severity Index (PASI). Results: Sixty-two patients (76% males) completed the questionnaire with a mean age (SD) of 40.4 (17.5) years. Overall, 39% of the patients used only topical and 48% received systemic non-biological therapy in the past 12 months. Median EQ-5D, EQ VAS, DLQI and PASI scores were 0.73, 60, 8 and 11.75, respectively. Out of the 62 patients, 18%, 26%, 28%, 63%, and 63% reported some or severe problem in mobility, self-care, usual activities, pain/discomfort and anxiety/depression, respectively. EQ-5D and EQ VAS correlated moderately with DLQI (rs = -0.44 for both, p <0.001), but only EQ VAS correlated significantly with PASI (rs = -0.31, p <0.01). Conclusion: This is the first study from Iran that assesses HRQOL in adult patients with psoriasis by EQ-5D and EQ VAS. Reduction in general HRQOL measured with EQ-5D and EQ-VAS is considerable, mostly in anxiety/depression and pain/discomfort dimensions. EQ-5D scores evaluated in this study provide country-specific data for economic evaluations.

Original languageEnglish
Pages (from-to)153-159
Number of pages7
JournalArchives of Iranian Medicine
Volume18
Issue number3
Publication statusPublished - Mar 1 2015

Fingerprint

Psoriasis
Health Status
Cross-Sectional Studies
Quality of Life
Visual Analog Scale
Iran
Dermatology
Anxiety
Depression
Pain
Self Care
Cost-Benefit Analysis
Outpatients
Outcome Assessment (Health Care)

Keywords

  • DLQI
  • EQ-5D
  • Health-related quality of life
  • Iran
  • Psoriasis

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Health status and quality of life in patients with psoriasis : An Iranian cross-sectional survey. / Moradi, Mahshid; Rencz, Fanni; Brodszky, Valentin; Moradi, Ahmad; Balogh, Orsolya; Gulácsi, L.

In: Archives of Iranian Medicine, Vol. 18, No. 3, 01.03.2015, p. 153-159.

Research output: Contribution to journalArticle

Moradi, M, Rencz, F, Brodszky, V, Moradi, A, Balogh, O & Gulácsi, L 2015, 'Health status and quality of life in patients with psoriasis: An Iranian cross-sectional survey', Archives of Iranian Medicine, vol. 18, no. 3, pp. 153-159.
Moradi, Mahshid ; Rencz, Fanni ; Brodszky, Valentin ; Moradi, Ahmad ; Balogh, Orsolya ; Gulácsi, L. / Health status and quality of life in patients with psoriasis : An Iranian cross-sectional survey. In: Archives of Iranian Medicine. 2015 ; Vol. 18, No. 3. pp. 153-159.
@article{804988ff8712411e8f3ce89df6e44980,
title = "Health status and quality of life in patients with psoriasis: An Iranian cross-sectional survey",
abstract = "Background: Psoriasis has a significant negative impact on patients’ health-related quality of life (HRQOL). This study aims to evaluate HRQOL of adult patients with psoriasis in Iran, and explore the relationship between general and disease-specific outcome measures in psoriasis. Methods: Between May and August 2013, a cross-sectional questionnaire survey of consecutive outpatients was conducted at a single clinic in Shiraz, Iran. HRQOL was assessed by the general measure EuroQol 5 dimensions (EQ-5D), visual analogue scale (EQ VAS), and the disease-specific Dermatology Life Quality Index (DLQI). Disease severity was measured by the Psoriasis Area and Severity Index (PASI). Results: Sixty-two patients (76{\%} males) completed the questionnaire with a mean age (SD) of 40.4 (17.5) years. Overall, 39{\%} of the patients used only topical and 48{\%} received systemic non-biological therapy in the past 12 months. Median EQ-5D, EQ VAS, DLQI and PASI scores were 0.73, 60, 8 and 11.75, respectively. Out of the 62 patients, 18{\%}, 26{\%}, 28{\%}, 63{\%}, and 63{\%} reported some or severe problem in mobility, self-care, usual activities, pain/discomfort and anxiety/depression, respectively. EQ-5D and EQ VAS correlated moderately with DLQI (rs = -0.44 for both, p <0.001), but only EQ VAS correlated significantly with PASI (rs = -0.31, p <0.01). Conclusion: This is the first study from Iran that assesses HRQOL in adult patients with psoriasis by EQ-5D and EQ VAS. Reduction in general HRQOL measured with EQ-5D and EQ-VAS is considerable, mostly in anxiety/depression and pain/discomfort dimensions. EQ-5D scores evaluated in this study provide country-specific data for economic evaluations.",
keywords = "DLQI, EQ-5D, Health-related quality of life, Iran, Psoriasis",
author = "Mahshid Moradi and Fanni Rencz and Valentin Brodszky and Ahmad Moradi and Orsolya Balogh and L. Gul{\'a}csi",
year = "2015",
month = "3",
day = "1",
language = "English",
volume = "18",
pages = "153--159",
journal = "Archives of Iranian Medicine",
issn = "1029-2977",
publisher = "Academy of Medical Sciences of I.R. Iran",
number = "3",

}

TY - JOUR

T1 - Health status and quality of life in patients with psoriasis

T2 - An Iranian cross-sectional survey

AU - Moradi, Mahshid

AU - Rencz, Fanni

AU - Brodszky, Valentin

AU - Moradi, Ahmad

AU - Balogh, Orsolya

AU - Gulácsi, L.

PY - 2015/3/1

Y1 - 2015/3/1

N2 - Background: Psoriasis has a significant negative impact on patients’ health-related quality of life (HRQOL). This study aims to evaluate HRQOL of adult patients with psoriasis in Iran, and explore the relationship between general and disease-specific outcome measures in psoriasis. Methods: Between May and August 2013, a cross-sectional questionnaire survey of consecutive outpatients was conducted at a single clinic in Shiraz, Iran. HRQOL was assessed by the general measure EuroQol 5 dimensions (EQ-5D), visual analogue scale (EQ VAS), and the disease-specific Dermatology Life Quality Index (DLQI). Disease severity was measured by the Psoriasis Area and Severity Index (PASI). Results: Sixty-two patients (76% males) completed the questionnaire with a mean age (SD) of 40.4 (17.5) years. Overall, 39% of the patients used only topical and 48% received systemic non-biological therapy in the past 12 months. Median EQ-5D, EQ VAS, DLQI and PASI scores were 0.73, 60, 8 and 11.75, respectively. Out of the 62 patients, 18%, 26%, 28%, 63%, and 63% reported some or severe problem in mobility, self-care, usual activities, pain/discomfort and anxiety/depression, respectively. EQ-5D and EQ VAS correlated moderately with DLQI (rs = -0.44 for both, p <0.001), but only EQ VAS correlated significantly with PASI (rs = -0.31, p <0.01). Conclusion: This is the first study from Iran that assesses HRQOL in adult patients with psoriasis by EQ-5D and EQ VAS. Reduction in general HRQOL measured with EQ-5D and EQ-VAS is considerable, mostly in anxiety/depression and pain/discomfort dimensions. EQ-5D scores evaluated in this study provide country-specific data for economic evaluations.

AB - Background: Psoriasis has a significant negative impact on patients’ health-related quality of life (HRQOL). This study aims to evaluate HRQOL of adult patients with psoriasis in Iran, and explore the relationship between general and disease-specific outcome measures in psoriasis. Methods: Between May and August 2013, a cross-sectional questionnaire survey of consecutive outpatients was conducted at a single clinic in Shiraz, Iran. HRQOL was assessed by the general measure EuroQol 5 dimensions (EQ-5D), visual analogue scale (EQ VAS), and the disease-specific Dermatology Life Quality Index (DLQI). Disease severity was measured by the Psoriasis Area and Severity Index (PASI). Results: Sixty-two patients (76% males) completed the questionnaire with a mean age (SD) of 40.4 (17.5) years. Overall, 39% of the patients used only topical and 48% received systemic non-biological therapy in the past 12 months. Median EQ-5D, EQ VAS, DLQI and PASI scores were 0.73, 60, 8 and 11.75, respectively. Out of the 62 patients, 18%, 26%, 28%, 63%, and 63% reported some or severe problem in mobility, self-care, usual activities, pain/discomfort and anxiety/depression, respectively. EQ-5D and EQ VAS correlated moderately with DLQI (rs = -0.44 for both, p <0.001), but only EQ VAS correlated significantly with PASI (rs = -0.31, p <0.01). Conclusion: This is the first study from Iran that assesses HRQOL in adult patients with psoriasis by EQ-5D and EQ VAS. Reduction in general HRQOL measured with EQ-5D and EQ-VAS is considerable, mostly in anxiety/depression and pain/discomfort dimensions. EQ-5D scores evaluated in this study provide country-specific data for economic evaluations.

KW - DLQI

KW - EQ-5D

KW - Health-related quality of life

KW - Iran

KW - Psoriasis

UR - http://www.scopus.com/inward/record.url?scp=84924423705&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84924423705&partnerID=8YFLogxK

M3 - Article

C2 - 25773688

AN - SCOPUS:84924423705

VL - 18

SP - 153

EP - 159

JO - Archives of Iranian Medicine

JF - Archives of Iranian Medicine

SN - 1029-2977

IS - 3

ER -